Guardian Technologies International Inc. announced that its Software Quality Assurance Team has completed all unit, component, integration, and systems tests of Signature Mapping TBDx(TM) (TBDx(TM)) in preparation for September clinical trials in South Africa. Under rigorous internal performance testing of 740 sputum slides, TBDx processed each slide in minutes while maintaining a consistently high bacilli detection level of over 90%, with false positives of less than 3%. In a global environment where sputum microscopy detection is only 20%-60% accurate and final results can take up to eight weeks, TBDx represents a diagnostic transformation towards automated detection of tuberculosis (TB). Further, the Signature Mapping platform can potentially be applied to all laboratory diagnostic procedures (i.e. malaria, leprosy, HIV, etc.). In April 2009, Guardian formed a medical advisory board of South African luminaries to assist in the development of specific global requirements and to advise on issues related to the detection of TB. TB is a pandemic worldwide challenge, further complicated by strains of drug resistant TB, which are being detected with increasing frequency. One-third of the world's population is infected with TB and up to ten million new cases are diagnosed worldwide annually. Someone dies from the disease every 20 seconds, accounting for approximately 2 million deaths annually. The World Health Organization annual estimates indicate $1 billion is spent annually to diagnose TB.

Guardian Technologies International Inc. filed its 10-K on March 31, 2009 for the period ending December 31, 2008. In this report its auditor, KBL, LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Guardian Technologies International Inc. announced that effective February 23, 2009, upon the recommendation of the company's Audit Committee, the company's Board of Directors approved the engagement of KBL LLP to serve as the company's registered independent public accountants and to be the principal registered independent public accountants to conduct the audit of the company's consolidated financial statements for the fiscal year ended December 31, 2008, replacing the firm of Bernkopf Goodman LLP.